Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innate Immune Response After Comirnaty JN.1 in Healthy Adults
2024-520304-26-00Phase 4Completed
- Sponsor
- University of Antwerp
- Start
- Mar 2025
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bretovameran in coronavirus disease 2019 (COVID-19), sponsored by University of Antwerp. Started Mar 2025; status: completed.
02
Drugs
bretovameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-520304-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520304-26-00.